{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-019658","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.945751+00:00","generated_at":"2026-05-16T00:11:31.776988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist Q4 net loss $44.4M ($0.69/share); rusfertide opt-out expected Q2 2026","bullets":["Q4 2025 net loss $44.4M ($0.69 per share) vs Q4 2024 net income $131.7M ($2.11 per share); FY2025 loss $130.1M ($2.05) vs FY2024 income $275.2M ($4.47).","License revenue fell to $7.4M in Q4 2025 from $170.6M in Q4 2024; FY2025 revenue $46.0M from $434.4M, due to lower milestones.","Cash, equivalents and marketable securities $646M as of Dec 31, 2025; provides runway through at least end of 2028.","Rusfertide NDA filed; company expects to opt out of the 50:50 profit/loss sharing with Takeda in a 90-day window opening in Q2 2026.","ICOTYDE regulatory decision anticipated in 2026 with potential launch this year; PN-881 Phase 1 completion by mid-2026; new preclinical candidates added."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-019658","json":"https://secwatch.observer/filing/0001104659-26-019658.json","markdown":"https://secwatch.observer/filing/0001104659-26-019658.md","text":"https://secwatch.observer/filing/0001104659-26-019658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926019658/0001104659-26-019658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926019658/tm267184d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:11:31.776988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}